Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Total Valuation
Castle Biosciences has a market cap or net worth of $573.73M. The enterprise value is $538.14M.
Market Cap$573.73M
Enterprise Value$538.14M
Share Statistics
Castle Biosciences has 28.84M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28.84M
Owned by Insiders2.78%
Owned by Instutions25.75%
Financial Efficiency
Castle Biosciences’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 1.52%.
Return on Equity (ROE)4.00%
Return on Assets (ROA)3.43%
Return on Invested Capital (ROIC)1.52%
Return on Capital Employed (ROCE)1.80%
Revenue Per Employee$436,358.739
Profits Per Employee$23,975.033
Employee Count761
Asset Turnover0.63
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Castle Biosciences is 40.57. Castle Biosciences’s PEG ratio is -0.31.
PE Ratio40.57
PS Ratio2.23
PB Ratio1.62
Price to Fair Value1.62
Price to FCF20.26
Price to Operating Cash Flow11.41
PEG Ratio-0.31
Income Statement
In the last 12 months, Castle Biosciences had revenue of $332.07M and earned $18.25M in profits. Earnings per share was $0.65.
Revenue$332.07M
Gross Profit$282.65M
Operating Income$8.67M
Pretax Income$21.56M
Net Income$18.25M
EBITDA38.14M
Earnings Per Share (EPS)0.65
Cash Flow
In the last 12 months, operating cash flow was $64.87M and capital expenditures -$28.33M, giving a free cash flow of $36.54M billion.
Operating Cash Flow$64.87M
Free Cash Flow$36.54M
Free Cash Flow per Share$1.27
Dividends & Yields
Castle Biosciences pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield4.94%
Earnings Yield2.46%
Stock Price Statistics
Beta0.70
52-Week Price Change5.02%
50-Day Moving Average22.41
200-Day Moving Average26.50
Relative Strength Index (RSI)53.57
Average Volume (3m)411.30K
Important Dates
Castle Biosciences upcoming earnings date is May 5, 2025, After Close.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 5, 2025
Ex-Dividend Date―
Financial Position
Castle Biosciences as a current ratio of 7.29, with Debt / Equity ratio of 0.06
Current Ratio7.29
Quick Ratio7.13
Debt to Market Cap0.04
Net Debt to EBITDA-2.45
Interest Coverage Ratio15.03
Taxes
In the past 12 months, Castle Biosciences has paid $3.32M in taxes.
Income Tax$3.32M
Effective Tax Rate15.39%
Enterprise Valuation
Castle Biosciences EV to EBITDA ratio is 16.96, with an EV/FCF ratio of 17.70.
EV to Sales1.95
EV to EBITDA16.96
EV to Free Cash Flow17.70
EV to Operating Cash Flow9.97
Balance Sheet
Castle Biosciences has $293.13M in cash and marketable securities with $16.60M in debt, giving a net cash position of -$276.53M billion.
Cash & Marketable Securities$293.13M
Total Debt$16.60M
Net Cash-$276.53M
Net Cash Per Share-$9.59
Tangible Book Value Per Share$12.59
Margins
Gross margin is 100.00%, with operating margin of 2.61%, and net profit margin of 5.49%.
Gross Margin100.00%
Operating Margin2.61%
Pretax Margin6.49%
Net Profit Margin5.49%
EBITDA Margin11.48%
EBIT Margin6.67%
Analyst Forecast
The average price target for Castle Biosciences is $39.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$39.00
Price Target Upside96.08%
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast51.09%
EPS Growth Forecast